TrinetX Study of Hypereosinophilic Syndrome (HES) without an identifiable non-haematological secondary cause

Study identifier:D3254R00004

ClinicalTrials.gov identifier:NCT06172751

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

TrinetX Study of Hypereosinophilic Syndrome (HES) without an identifiable non-haematological secondary cause

Medical condition

Hypereosinophilic Syndrome (HES)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

250

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 15 Dec 2023
Estimated Primary Completion Date: 01 May 2024
Estimated Study Completion Date: 01 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria